| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3193886 | Annals of Allergy, Asthma & Immunology | 2006 | 6 Pages |
Abstract
These results confirm and extend previous findings that desloratadine is safe and is associated with a statistically significant reduction in nasal and nonnasal symptoms in patients with PAR. Objective nasal airflow, evaluated by PNIF, was statistically significantly improved after desloratadine treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Kenneth MD, Gordon MD, Jacques MD, William MD, Barry PhD, Davis PhD,